This is evidenced by the same pharmacodynamic changes in Tie2 being reported in different laboratories that have analysed samples taken from patients with glioma [18], CRC [19] and gall bladder [20] cancer, who were treated with cediranib, a VEGF receptor Tyrosine Kinase inhibitor (VEGFR TKi). The gene discussed is TEK; the disease is colorectal carcinoma.